114 related articles for article (PubMed ID: 9088591)
1. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides.
McDowell G; Coutie W; Shaw C; Buchanan KD; Struthers AD; Nicholls DP
Br J Clin Pharmacol; 1997 Mar; 43(3):329-32. PubMed ID: 9088591
[TBL] [Abstract][Full Text] [Related]
2. Dose-ranging effects of candoxatril on elimination of exogenous atrial natriuretic peptide in chronic heart failure.
Motwani JG; Lang CC; Allen MJ; Johnson HF; Struthers AD
Clin Pharmacol Ther; 1993 Dec; 54(6):661-9. PubMed ID: 8275621
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure.
Elsner D; Müntze A; Kromer EP; Riegger GA
Am J Cardiol; 1992 Aug; 70(4):494-8. PubMed ID: 1386491
[TBL] [Abstract][Full Text] [Related]
4. Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure.
Kentsch M; Otter W; Drummer C; Nötges A; Gerzer R; Müller-Esch G
Eur J Clin Pharmacol; 1996; 51(3-4):269-72. PubMed ID: 9010697
[TBL] [Abstract][Full Text] [Related]
5. Clearance of brain natriuretic peptide in patients with chronic heart failure: indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor mechanism.
Lang CC; Motwani JG; Coutie WJ; Struthers AD
Clin Sci (Lond); 1992 Jun; 82(6):619-23. PubMed ID: 1320540
[TBL] [Abstract][Full Text] [Related]
6. Effects of renal neutral endopeptidase inhibition on sodium excretion, renal hemodynamics and neurohormonal activation in patients with congestive heart failure.
Kimmelstiel CD; Perrone R; Kilcoyne L; Souhrada J; Udelson J; Smith J; de Bold A; Griffith J; Konstam MA
Cardiology; 1996; 87(1):46-53. PubMed ID: 8631044
[TBL] [Abstract][Full Text] [Related]
7. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension.
O'Connell JE; Jardine AG; Davidson G; Connell JM
J Hypertens; 1992 Mar; 10(3):271-7. PubMed ID: 1315825
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of kidney neutral endopeptidase after administration of the neutral endopeptidase inhibitor candoxatril: quantitation by autoradiography.
Yoshida K; Kanazawa M; Casley DJ; Katopothis A; Johnston CI
J Cardiovasc Pharmacol; 1998 Nov; 32(5):702-8. PubMed ID: 9821842
[TBL] [Abstract][Full Text] [Related]
9. Evidence for a new role of natriuretic peptides: control of intraocular pressure.
Wolfensberger TJ; Singer DR; Freegard T; Markandu ND; Buckley MG; MacGregor GA
Br J Ophthalmol; 1994 Jun; 78(6):446-8. PubMed ID: 8060926
[TBL] [Abstract][Full Text] [Related]
10. Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure.
Wegner M; Hirth-Dietrich C; Stasch JP
Cardiovasc Res; 1996 Jun; 31(6):891-8. PubMed ID: 8759244
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure.
Northridge DB; Newby DE; Rooney E; Norrie J; Dargie HJ
Am Heart J; 1999 Dec; 138(6 Pt 1):1149-57. PubMed ID: 10577447
[TBL] [Abstract][Full Text] [Related]
12. Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure.
Northridge DB; Currie PF; Newby DE; McMurray JJ; Ford M; Boon NA; Dargie HJ
Eur J Heart Fail; 1999 Mar; 1(1):67-72. PubMed ID: 10937982
[TBL] [Abstract][Full Text] [Related]
13. Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin.
Ando S; Rahman MA; Butler GC; Senn BL; Floras JS
Hypertension; 1995 Dec; 26(6 Pt 2):1160-6. PubMed ID: 7498988
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of the natriuretic effects of neutral endopeptidase inhibition in Dahl salt-sensitive and salt-resistant rats.
Hirata Y; Suzuki E; Hayakawa H; Matsuoka H; Sugimoto T; Kangawa K; Matsuo H
J Cardiovasc Pharmacol; 1994 Feb; 23(2):283-90. PubMed ID: 7511759
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms underlying the augmented responses of deoxycorticosterone acetate-salt hypertensive rats to neutral endopeptidase inhibitors.
Hirata Y; Suzuki Y; Suzuki E; Hayakawa H; Kimura K; Goto A; Omata M; Minamino N; Kangawa K; Matsuo H
J Hypertens; 1994 Apr; 12(4):367-74. PubMed ID: 8064160
[TBL] [Abstract][Full Text] [Related]
16. Characterization of atrial natriuretic peptide in urine from rats treated with a neutral endopeptidase inhibitor.
Suzuki E; Hirata Y; Matsuoka H; Sugimoto T; Hayakawa H; Sugimoto T; Kangawa K; Minamino N; Matsuo H
Biochem Biophys Res Commun; 1992 Feb; 182(3):1270-6. PubMed ID: 1531753
[TBL] [Abstract][Full Text] [Related]
17. Influence of candoxatril on plasma brain natriuretic peptide in heart failure.
Lang CC; Motwani J; Coutie WJ; Struthers AD
Lancet; 1991 Jul; 338(8761):255. PubMed ID: 1676808
[No Abstract] [Full Text] [Related]
18. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension.
Bevan EG; Connell JM; Doyle J; Carmichael HA; Davies DL; Lorimer AR; McInnes GT
J Hypertens; 1992 Jul; 10(7):607-13. PubMed ID: 1321186
[TBL] [Abstract][Full Text] [Related]
19. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II.
Richards AM; Wittert GA; Crozier IG; Espiner EA; Yandle TG; Ikram H; Frampton C
J Hypertens; 1993 Apr; 11(4):407-16. PubMed ID: 8390508
[TBL] [Abstract][Full Text] [Related]
20. No effect of the oral neutral endopeptidase inhibitor candoxatril, on bronchomotor tone and histamine reactivity in asthma.
Angus RM; McCallum MJ; Nally JE; Thomson NC
Eur Respir J; 1994 Jun; 7(6):1084-9. PubMed ID: 7925877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
